Developing the Medicines of Tomorrow
Innovative R&D requires creativity as much as the discipline of hard science. Our team of dedicated scientists in biology, chemistry, pharmacology, translational medicine, and clinical science are excited by the challenges of creating tomorrow’s medicines. Their responsibility, and their passion, is to help the world’s cancer patients get the therapies they need.
Molecularly Targeted Agents
Breakthroughs in gene sequencing and other methods of tumor characterization have elevated the study of cancer to one of specific molecular characteristics – for example, abnormalities in HER2, BRCA, BRAF, ALK, and EGFR genes and proteins. The ability to identify specific disease subpopulations through mutations in certain genes and proteins is a critical advancement in oncology, making possible new treatments that are more effective than ever.
“Rational” drug design, in which targets are selected based on their observed role in cancer cell growth and survival, has been a cornerstone of our development efforts from the start. It has yielded three of our internally developed, molecularly targeted medicines/candidates: zanubrutinib, pamiparib, and lifirafenib.
Harnessing the body’s own immune system to fight cancer is a compelling and complex endeavor. Immune checkpoints are molecules on certain immune cells that are activated or inactivated to start an immune response.
Our research and development team focuses on the PD-1/PD-L1 axis, as well as other aspects of tumor-associated immune cells, to develop novel drug candidates that may enhance immune cells’ ability to mount a response against cancer cells. In addition, we are working to identify mechanisms by which tumors evade immune systems and target weak points in the cancer immunity cycle. Tislelizumab, for example, is an internally developed immune checkpoint inhibitor. In addition, Ociperlimab (BGB-A1217) (TIGIT) is our investigational humanized monoclonal antibody designed to bind to TIGIT with high specificity and affinity. TIGIT, or T-cell immunoreceptor with immunoglobulin and ITIM domain, is a promising target for cancer immunotherapy, with the potential to rescue immune cells from the immunosuppressive tumor microenvironment.
Targeted cancer treatments block essential biochemical pathways or mutant proteins that are required for tumor cell growth and survival. Still, other immune mechanisms within the body can impede a patient’s response.
Our R&D team is evaluating combination therapies that target distinct steps of anti-tumor immunity, exploring synergies that could result in stronger and more sustained responses in tumor destruction. We believe that combining immuno-oncology (I-O) agents with targeted treatments may lead to more durable responses and improved survival rates. With an innovative biology-based approach and advanced cancer models built to test I-O combination therapies efficiently, we are working to discover the next generation of cancer treatments.
We continually explore the role of our internally developed drug candidates in combination therapy treatments across oncology. For example, we believe there is a strong rationale supporting combinations of our anti-PD-1 antibody tislelizumab with some of our clinical stage assets, as well as combinations of our BTK inhibitor, zanubrutinib, with other assets.
Investigator Sponsored Research
We are committed to patient-focused and science-driven research to discover and develop new therapies for underserved populations and markets.
Investigator Sponsored Research (ISR) describes a study initiated and conducted by a qualified research investigator or sponsor, alone or in collaboration with others, and provides direction related to the administration, dispensing, and appropriate use of drugs for research. Our ISR program supports research including non-clinical, clinical, health economics and outcomes research, and non-interventional studies (real world evidence).
Independent Medical Education Grants
We recognize the essential role educational programs play in enabling healthcare professionals at all levels to contribute to improved patient outcomes by advancing their skills and knowledge. We therefore are proud to support a range of independent medical educational (accredited and unaccredited) programs. We focus on high-quality, evidence-based programs and activities that complement therapeutic areas in which we focus our own research and development.
Organizations We Support
We accept proposals from a variety of independent educational providers that identify unmet educational needs and demonstrate how a proposed program might address these needs.
Unbiased and Independent
Responsibility for and control over the selection, content, faculty, educational methods, materials, and venue for an independent medical education program belong solely to the program organizers. We do not provide advice or guidance to the independent medical education provider for any program for which we have granted funding.
Inquiries about our Independent Medical Education program and/or the submission process should be directed to the BeiGene Independent Medical Education Administrator at IMEGrants@BeiGene.com.
BioIsland Innovation Center at Guangzhou’s BioIsland
Our goal for the BioIsland Innovation Center (BIC) is to support the accelerated development of externally generated inventions. We plan to do so by providing venture funding, incubator space, and other resources critical to emerging companies. In return, we expect BIC will give us access to new opportunities to help develop potentially groundbreaking medical advancements.
With a state-of-the-art research center and modern office space in a vibrant and growing biotechnology innovation cluster, BIC was conceived as an innovation hub with the capacity to accommodate more than 30 early-stage companies with upwards of 500 scientist-entrepreneurs.
To learn more about partnering at the BioIsland Innovation Center, please contact BioIsland@BeiGene.com.